Market Report Source

Overview

Introduction

Optimer Pharmaceuticals (Optimer) focuses on the discovery, development and global commercialization of anti-infective products for the treatment of serious infectious diseases. The company currently has two late stage anti-infective product candidates in Phase III trials – OPT-80 (Difimicin) and Prulifloxacin.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Optimer in-licensed Difimicin from Par Pharmaceuticals and Prulifloxacin from Nippon Shinyaku. In addition, the company has acquired OPopS technology from The Scripps Research Institute. Utilizing the OPopS technology the company is developing Difimicin and other internal products. During 2004-06, total revenue growth was nearly constant derived from sole revenue stream, license fees, collaboration.The decline in revenues from $2 in 2005 to $1 million in 2006 was due to lowered Small Business Innovation Research Program grants and It terminated manufacturing supply agreement with Sloan-Kettering Institute for Cancer Research. Optimer’s total revenues during 2006-2010 are forecasted to record an absolute growth of +$97 million with sales increasing from $1 million to $98 million grows at a CAGR of 21%. The increase would be primarily due to the forecasted revenues from Difimicin and Prulifloxacin.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Company Financials
P&L
Balance Sheet
Cash Flow
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Product Discovery and Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview
Appendix
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Optimer Pharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: Optimer Pharmaceuticals- Key Strategic Revenues, 2006-2010 ($ Mn)

TABLES
Table 1: Optimer Pharmaceuticals – Key Facts
Table 2: Optimer Pharmaceuticals – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 3: Optimer Pharmaceuticals – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 4: Optimer Pharmaceuticals – Balance Sheet
Table 5: Optimer Pharmaceuticals – Cash Flow
Table 6: Optimer Pharmaceuticals – In-house Pipeline Products
Table 7: Optimer Pharmaceuticals – Collaboration Products
Table 8: Optimer Pharmaceuticals – Forecast Sales, 2006-2010 ($ Mn)
Table 9: Optimer Pharmaceuticals – Key Competitors
Table 10: Optimer Pharmaceuticals – Key Suppliers
Table 11: Optimer Pharmaceuticals – Key Clients
Table 12: Optimer Pharmaceuticals – Key Shareholders
Table 13: Optimer Pharmaceuticals – SWOT Analysis Summary
Table 14: Optimer Pharmaceuticals – Value Chain Analysis
Table 15: Optimer Pharmaceuticals – Scorecard
Table 16: Optimer Pharmaceuticals – Key Employees
Table 17: Optimer Pharmaceuticals – Financial and Operational Overview